Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1Available 1Approved for marketing 1

Sponsor Class

OTHER 23NIH 4INDUSTRY 4NETWORK 3

Study Type

Interventional 2Expanded_access 2

Sponsor

Cancer Type

CNS 4Endocrine 2

Conditions

Pheochromocytoma 5Paraganglioma 4Neuroblastoma 4Neuroendocrine Tumors 2Neuroectodermal Tumors 1Neoplasms 1Disease 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × 3-Iodobenzylguanidine × Clear all
NCT01590680 2023-02-28

Expanded Access Protocol Using 131I-MIBG

Jubilant DraxImage Inc.

Available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown
60 enrolled
CNS

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

NCT00126412 2019-05-31

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

GE Healthcare

Phase 3 Completed
251 enrolled
CNSEndocrine

Disease, Neuroblastoma, Pheochromocytoma

NCT00730444 2009-11-09

Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

GE Healthcare

Approved for marketing
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡